NewBio Therapeutics focuses on the R&D of monoclonal antibody and antibody-drug conjugate (ADC) as anti-cancer therapeutics . We have established a highly efficient antibody-drug conjugate technology platform, and can conduct antibody and ADC drug discovery from target selection to IND enabling study. We also have set up an efficient antibody screening platform, and developed innovative site-specific linker technology and proprietary high-potency cytotoxic drugs as new ADC payloads. We have built up an innovative and strong ADC drug pipeline, based on which NewBio Therapeutics will grow to an outstanding biopharmaceutical company.